📅 PUBMED DAILY TRIAGE — 2026-05-21 (Thursday)

Window: 2026-05-20T09:00Z → 2026-05-21T09:00Z (CRDT)
Topics scanned: 10 | Articles reviewed in depth: ~70 | Candidates evaluated: ~69
High priority: 5 | Standard: 14 | Low/archive: ~20 | Unsolicited finds: 0
Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

TR-2026-05-21-001 / PMID 42160759 · Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial · 8/10 · 🟠 NOVEL_TREATMENT
Phase II multicenter trial demonstrates 54% ORR (4 CRs) with durable responses in R/R ENKTL — a rare aggressive lymphoma with minimal effective second-line options; PD-L1 alterations predict response.
Blood Adv · Makita S et al.

TR-2026-05-21-005 / PMID 42160138 · RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma · 8/10 · 🟠 NOVEL_TREATMENT
First comprehensive multiomic characterization of myeloid sarcoma (AML subtype in ~20% of patients); establishes RAS pathway as universal therapeutic target; ctDNA proof-of-concept enables non-invasive molecular profiling of this historically biopsy-inaccessible disease.
Blood Cancer Discov · Nadorp B et al. (NYU, MD Anderson, Ohio State, Mount Sinai)

Early Cancer Detection (Liquid Biopsy / ctDNA)

TR-2026-05-21-003 / PMID 42160635 · Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk NMIBC receiving BCG · 8/10 · 🔴 EARLY_CANCER_DETECTION
Post-BCG utDNA positivity: 12-month RFS 25% vs 91% (HR=10.0); 4.1-month lead time over standard surveillance; directly actionable for identifying patients needing treatment intensification.
J Urol · Bahlburg H et al. (UBC, Helsinki)

TR-2026-05-21-004 / PMID 42158852 · Ultra-sensitive detection of mutant KRAS in circulating tumor DNA predicts survival in resectable pancreatic adenocarcinoma · 7/10 → HIGH (flag) · 🔴 EARLY_CANCER_DETECTION
Ultra-deep sequencing (≥100,000x) detects 46% more KRAS mutations in localized PDAC vs standard depth; only ultra-deep approach significantly predicts OS (HR 3.13); outperforms serum CA 19-9.
Front Oncol · Cox M et al. (Northwestern) · PMC: 13180577

Rare Diseases

TR-2026-05-21-002 / PMID 42160453 · Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension · 8/10 · 🟡 UNDERSERVED_POPULATION
Validates a practical peripheral blood BMPR-II biomarker panel for PAH clinical trials; critically reveals sotatercept (FDA-approved) works by depleting circulating BMP9/10 rather than restoring BMPR-II — unexpected mechanism with implications for understanding treatment response.
Sci Transl Med · Jones RJ et al. (Cambridge, Imperial, Vanderbilt)

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• TR-2026-05-21-006 / PMID 42160693 · HMA+VEN real-world outcomes in Pakistan (AML/MDS, n=96) · 6/10 · LMIC equity data; OS 77.4% AML at 2 years
• TR-2026-05-21-007 / PMID 42159922 · FDG PET/CT SUVmax >14.5 independently predicts POD24 and inferior PFS in FL (n=119) · 6/10 · Practical metabolic risk tool
• TR-2026-05-21-008 / PMID 42160756 · Anti-CCRL2 ADC for TP53-mutated MDS/AML, outperforms gemtuzumab preclinically · 5/10 (non-human cap) · Novel target, major unmet need
• TR-2026-05-21-018 / PMID 42160424 · CD20 EryPatch living cellular patch for B cell depletion (Sci Adv) · 5/10 (non-human cap) · Conceptually novel anti-CD20 approach
• TR-2026-05-21-019 / PMID 42160758 · Tumor-platelet crosstalk: mechanisms, thrombosis, platelet RNA liquid biopsy · 5/10 · Review; platelet RNA cancer detection angle

Early Cancer Detection

• TR-2026-05-21-009 / PMID 42159904 · ctDNA RAS mutations + IL-8 predict worse OS in mCRC second-line FOLFIRI+RAM (n=41) · 6/10 · RAS emergence in 44% of RAS wild-type tissue cases
• TR-2026-05-21-010 / PMID 42158727 · PTLD biomarkers (ctDNA, ZEBRA antigen, LMP1 variants) for EBV-negative forms · 5/10 · Review; PMC open

AI/ML in Clinical Diagnostics

• TR-2026-05-21-011 / PMID 42160777 · ML for SGLT2i treatment failure prediction in T2D (n=62,222); SHAP 9-feature risk score · 7/10 · Largest real-world SGLT2i ML cohort
• TR-2026-05-21-012 / PMID 42160781 · xAI in cancer imaging scoping review (371 studies): fragmented methods, 17.5% reproducibility · 6/10 · Evidence base for standardization
• TR-2026-05-21-013 / PMID 42160740 · AI-cardiologist alignment in stress echo (PROTEUS RCT, n=854): 60% agreement, worse in comorbid patients · 6/10 · Real-world AI deployment insight

Novel Therapeutics

• TR-2026-05-21-014 / PMID 42160700 · Cellular therapies in solid tumors (TIL/TCR/CAR) after 2024 FDA approvals: practice framework · 5/10 · Review; JCO Oncol Pract

Cardiovascular-Metabolic

• TR-2026-05-21-016 / PMID 42160776 · NoHoW digital weight maintenance RCT (n=1,627, 3-country): null result for digital behavior change interventions · 6/10 · Rigorous null RCT

Aging & Longevity

• TR-2026-05-21-015 / PMID 42160766 · 18-marker blood biomarker signature predicts 12-year mortality (HR 1.89), frailty, CVD in aging (TILDA+HRS, n=8,875) · 7/10 · Cross-national validation; Age and Ageing

Rare Diseases

• TR-2026-05-21-017 / PMID 42158842 · ML comorbidity clustering in rare disease patients (UK Biobank): 12 unique patterns vs 14 in general population · 6/10 · PMC open

💡 UNSOLICITED FINDS

None today — all high-signal articles matched at least one watchlist topic.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 4 · Treatment Innovation: 4 · Diagnostics: 5 · Drug Development: 2 · Prevention: 2 · Genomics/Precision Medicine: 1 · Public Health: 1

By evidence maturity:

• Validated: 8 · Exploratory: 11 · Potentially Practice-Changing: 0 (sotatercept mechanism finding noted as potentially impactful)

By watchlist topic — reviewed / HIGH / best score:

By source type: peer_reviewed 19 | preprint 0
Alert cap: 5/5 alerts sent (alert cap reached; 5 HIGH total)

Topics with zero 8+ articles today: CBC/ML hematology, AI/ML diagnostics, Precision oncology, Cardiovascular-metabolic, Aging/longevity, Sentinel scan

🔧 RUN NOTES

• Window expansion: NOT triggered — 5 HIGH articles found in standard 24h window.
• Truncation: AI/ML diagnostics (137→10), Novel therapeutics (96→10), Cardiovascular (112→10), Precision oncology (59→10), Sentinel scan (700→6) all truncated; most relevant candidates reviewed first.
• CBC/ML hematology — 7th consecutive zero HIGH: Only 2 results in full search window; abstracts for PMIDs 42159081 and 42158646 not retrieved. Query reformulation strongly recommended — consider broadening to include "differential count" OR "morphology" OR "hematogram" and removing the triple-AND construction which may be over-constraining daily indexing.
• Aging/longevity: humans[MeSH] filter effective — 34 results (manageable); human-relevant articles dominated first page.
• Myeloid sarcoma finding (PMID 42160138): Particularly notable — this AML subtype (~20% of patients) has been systematically excluded from clinical trials and lacked genomic characterization. RAS pathway universality is actionable.
• Sotatercept mechanism (PMID 42160453): The finding that sotatercept reduces (not restores) BMPR-II signaling challenges the drug's stated mechanism and may affect how Phase 3 data (STELLAR trial) is interpreted — flags for downstream analysis.
• Rolling 7-day CBC/ML high-priority record: 0/7 consecutive days — action required on query.
• Data quality: No retraction notices, editorials, or low-grade publication types in HIGH articles; all from high-impact, peer-reviewed journals.